Key Points
- Director Rowan Chapman sold 122 shares on March 13 at an average price of $191.38 for $23,348.36, trimming his stake by 2.08% to 5,752 shares (disclosed in an SEC filing).
- Natera beat expectations last quarter with EPS of $0.35 (vs. consensus -$0.46) and revenue of $665.5M (vs. $600.68M estimate), though the company still posts a negative PE (-129.66) and negative net margin.
- Wall Street sentiment is largely positive, with a MarketBeat consensus rating of Moderate Buy and a consensus price target of $253.47 after multiple firms raised their targets.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Rowan Chapman sold 122 shares of the firm's stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $191.38, for a total transaction of $23,348.36. Following the sale, the director owned 5,752 shares of the company's stock, valued at approximately $1,100,817.76. The trade was a 2.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Natera Trading Up 0.4%
NASDAQ:NTRA opened at $198.38 on Wednesday. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36. The firm's 50 day moving average is $217.92 and its 200 day moving average is $207.15. The stock has a market capitalization of $28.12 billion, a PE ratio of -129.66 and a beta of 1.65.
Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The business had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. During the same period in the prior year, the company earned ($0.41) earnings per share. Research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on NTRA shares. Barclays boosted their price objective on Natera from $230.00 to $270.00 and gave the company an "overweight" rating in a research note on Monday, December 15th. JPMorgan Chase & Co. upped their price target on shares of Natera from $250.00 to $260.00 and gave the company an "overweight" rating in a research note on Monday, December 15th. Wells Fargo & Company lifted their price objective on shares of Natera from $205.00 to $215.00 and gave the company an "equal weight" rating in a research note on Friday, February 27th. Robert W. Baird boosted their target price on shares of Natera from $239.00 to $257.00 and gave the company an "outperform" rating in a report on Friday, February 27th. Finally, Zacks Research upgraded Natera from a "strong sell" rating to a "hold" rating in a research report on Thursday, January 1st. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $253.47.
View Our Latest Research Report on NTRA
Institutional Investors Weigh In On Natera
Institutional investors and hedge funds have recently modified their holdings of the company. Reflection Asset Management purchased a new position in Natera during the fourth quarter valued at approximately $29,000. Palladiem LLC purchased a new position in shares of Natera during the 4th quarter valued at $31,000. Bank of Jackson Hole Trust increased its holdings in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock worth $37,000 after purchasing an additional 83 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in shares of Natera in the fourth quarter worth $39,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in shares of Natera in the fourth quarter worth $41,000. 99.90% of the stock is owned by hedge funds and other institutional investors.
About Natera
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
